Poor bedaquiline response in drug-resistant TB in South Africa
Official title: Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa
Funded at Vanderbilt University Medical Center · NIH-11519237 · Data updated 2026-11-12
This project looks at why some people with drug-resistant tuberculosis in South Africa don’t respond well to bedaquiline and what factors predict worse outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $137,406 |
| NIH project number | 3R01AI158605-06S1 |
| Project ID | NIH-11519237 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rifampicin-resistant TB in South Africa treated with bedaquiline-containing regimens.
✕Less likely to help
Patients not receiving bedaquiline-based therapy or not in South Africa may not benefit from these findings.
What this research studies
The research uses data from South Africa’s national lab and drug-resistant TB registry to study patients treated with bedaquiline-containing regimens. It will analyze routine specimens to identify why treatment sometimes fails and which factors are linked to poor results. The investigators will perform standard drug susceptibility testing on bedaquiline and companion drugs to understand resistance patterns. The goal is to map predictors of delayed culture conversion and unfavorable outcomes in real-world, programmatic settings. This work could help tailor treatments and improve success rates for RR-TB patients.
Why it matters
Potential benefit: If successful, findings could guide more effective bedaquiline-based regimens and improve outcomes for patients with rifampicin-resistant TB.
How similar studies have gone: Previous studies showed improved outcomes with bedaquiline, but predictors of poor response in programmatic settings remain less clear.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Van Der Heijden, Yuri F. — Vanderbilt University Medical Center
- Study coordinator: Van Der Heijden, Yuri F.
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.